Pfizer creates chief operating officer role for Bourla
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500, Nasdaq set for weekly fall as chip stocks slide
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
AstraZeneca (AZN) Granted FDA Aprproval for FASLODEX (fulvestrant) in Combination with Abemaciclib
November 15, 2017 7:01 AM ESTAstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved a new indication for FASLODEX® (fulvestrant), expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (MBC) in women with disease progression after endocrine therapy.1
Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit, said: FASLODEX has long been an effective monotherapy option for women with hormone receptor positive breast cancer, which is the... More
